Newsroom

Sorted by: Latest

-

Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026

MUNICH--(BUSINESS WIRE)--Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Meeting, being held May 29 - June 2, 2026, in Chicago. The presentation by Prof. Dr. Toon Van Gorp, clinical investigator of the study, will provide an update of maturing data from the ongoing dose escalation part of the ova...
-

White Castle Partners with Automated Retail Technologies to Bring Iconic Sliders to Automated Kiosks Nationwide

COLUMBUS, Ohio & SARASOTA, Fla.--(BUSINESS WIRE)--White Castle partners with Automated Retail Technologies to bring hot, ready-to-eat Sliders to automated Crave & Go kiosks nationwide....
-

Blain’s Farm & Fleet Celebrates Spring with Blain’s Fest 2026

JANESVILLE, Wis.--(BUSINESS WIRE)--Blain’s Farm & Fleet Celebrates Spring with Blain’s Fest 2026...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - May 20.04.2026 GMAY.LN IE000P0FL8E3 900,002.00 USD 35,397,162.55 39.330  ...
-

Atropos Health Creates World’s Largest Body of Medical Evidence, Alexandria, for Clinical Decision Support and LLM Training to Improve Patient, Life Science, and Medical Outcomes

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the world’s largest creator of real-world evidence (RWE) for clinical decision making, today announced the availability of the largest source of novel medical content - with over 33M artifacts of evidence generated by a high-throughput, standardized observational evidence-creation workflow. Alexandria®, the Atropos Evidence™ Library, is slated to grow to two billion pEBFs by the end of 2026, exceeding all known medical evidence by 100x in volu...
-

Avem Partners Completes Acquisition of PAMCO

LOS ANGELES--(BUSINESS WIRE)--Avem Partners (“Avem”), a private equity firm focused on lower middle market aerospace and defense businesses, today announced the completion of its acquisition of Precision Aircraft Machining Company, Inc. (“PAMCO”). True West Capital Partners, alongside several prominent family offices, and other high net-worth individuals provided capital in support of this acquisition, which included significant investment from Avem principals and several aerospace industry exe...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 20.04.2026 FTMO.LN IE000CY30YV9 3,050,002.00 USD 87,284,769.77 28.618  ...
-

Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification

URBANA, Ill.--(BUSINESS WIRE)--Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRI...
-

Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting

LARKSPUR, Calif.--(BUSINESS WIRE)--AulosTM Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Phase 1/2 data from its ongoing study of imneskibart will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The presentation will focus on promising results for imneskibart with and without nivolumab in checkpoint inhibitor (C...
-

MSI Achieves CMMC Certification

BOSTON--(BUSINESS WIRE)--MOCA Systems, Inc. (MSI) today announced that its services division, MOCA Services, has achieved Cybersecurity Maturity Model Certification (CMMC) Level 2, validating the company’s ability to protect Controlled Unclassified Information (CUI) in accordance with Federal requirements. MSI is among the first program management and owner’s representative firms to achieve CMMC Level 2 certification, which it received after completing a rigorous audit by a Certified Third-Part...